Articles On Rhythm Biosciences (ASX:RHY)

Cancer diagnostics technology company Rhythm Biosciences (RHY) withdraws its TGA application for its ColoSTAT technology The withdrawal comes after the company received feedback from the TGA and concluded it wouldn’t be able to answer al...

Rhythm plunged 45% this morning after announcing some TGA news The FDA has cleared PYC Therapeutics for first ever human trial on Retinitis Pigmentosa Type 11   Rhythm Biosciences (ASX: RHY) crashed 47% this morning after withdrawing its...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX got an Data Nerd Bailout when the ABS dropped happy-ish CPI data The benchmark recovers from early flesh wounds to end the day flat Ordinary Aussies ‘outraged’ over changes to super that will never, ever affect them The market has...

Zelira Therapeutics (ZLD) promotes Greg Blake to the role of Executive Director Mr Blake joined the company in 2020 and has been serving as Vice President, Global Head of Commercial and Partnering After more than 20 years working in t...

Rhythm Biosciences (RHY) retains its ISO certification for a fifth consecutive year The certification means Rhythm has met the international standard for in-vitro diagnostics and medical devices for its ColoSTAT blood test product Rh...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Rhythm Biosciences (RHY) appoints a second bioanalytical partner to advance its development program into additional cancer areas    The company has been working to develop simple, affordable and highly accurate blood tests for the detection...

Rhythm partners with the Baker Institute to expand cancer program Island Pharma gets ethics approval in the US   Rhythm Biosciences (ASX:RHY) will advance a development program into additional cancers after appointing the Baker Institute...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Australian health stocks sightly up for the week with optimistism of a traditional end-of-year rally In positive news several healthcare names deliver strong quarterly results and forecasts Morgans upgrades Nanonosonics from Hold to Add an...

ShareCafeA sea of red in today’s trading: ASX closes 1.84% lower by Peter Milios   All but one sector finished lower today, as the ASX reacted to the overnight news that the Fed has increased rates by 75 basis points. Materials, Consumer Di...

The All Ordinaries Index (ASX: XAO) is 1.85% in the red today, but these four All Ords shares are soaring higher. The A2 Milk Company Ltd (ASX: A2M), Perpetual Ltd (ASX: PPT), RHYTHM Biosciences Ltd (ASX: RHY) and Weebit Nano Ltd (ASX:...

ShareCafeAll red across the board following US rate hike sentiment: ASX down 1.96% at noon By Lauren Hayes   US equities plunged after Fed Chair Jerome Powell indicated policymakers would continue raising interest rates to fight persistent...

ShareCafeStocks of the Hour: RHY, A2M, NFL                    Rhythm Biosciences Ltd (ASX:RHY) confirmed this morning the expansion of its international regulatory footprint, having successfully registered ColoSTAT® with the New Zeala...

The All Ordinaries Index (ASX: XAO) may be sinking today but that hasn’t stopped a couple of ASX healthcare shares from racing higher. Here’s why these two All Ords shares are smashing the index on Thursday: Immutep Ltd (ASX: IMM) The...

HitIQ signs deal with Western Australian Football Commission Rhthym Bio expands into NZ Immutep’s Phase II TACTI-002 trial has been accepted for an oral presentation HitIQ signs with WAFC Concussion tech specialist HitIQ (ASX:HIQ) rose 40...

03 Nov 2022 - A snapshot of the stocks on the move featuring Rhythm Biosciences (ASX:RHY), The a2 Milk Company (ASX:A2M) and Norfolk Metals (ASX:NFL).

Rhythm Biosciences (RHY) successfully registers its ColoSTAT cancer detection product with the New Zealand national database of Medical DevicesThe registration allows the technology to be marketed and sold in the countryColoSTAT is a low-co...

Cancer diagnostics technology company, Rhythm Biosciences (ASX:RHY), has secured authorisation for ColoSTAT in New Zealand.

Highlights The ASX 200 benchmark index closed down today (21 October), losing 53.90 points or 0.80% to end at 6,676.80 points. Over the last five days, the index has lost 1.21% and 9.96% over the last 52 weeks. Utilities and materials...

Rhythm Biosciences (RHY) receives a $2.7 million research and development tax refundThe funds comes as part of the Australian government’s research and development tax incentive, which recognises R&D undertaken during the financial year...

Billionaire investor Alex Waislitz tops up holding in Thorney Technologies which now has a stake in Splitit Data Analytics company Nuix sees its CEO bullish on the company, which is the target of takeover speculation Carsales.com has seen...

The Rhythm Biosciences Ltd (ASX: RHY) share price is in the green during morning trade on Friday. This comes after the ASX All Ords company announced that its executive chair has just offloaded $6.5 million worth of his shares. At the ti...

As with your columnist, plenty of other Australians aged between 50 and 74 are suffering from “poo-crastination”. Every two years, anyone in that cohort receives a bowel cancer test kit from the Federal Health Department, which requires the...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Pac Partners...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Rhythm Biosciences (RHY) completes its initial biomarker review to support platform expansion of its core detection technology, ColoSTAT With the first phase of the expansion complete, the company will turn its focus on accelerating the ne...

Highlights Rhythm Biosciences has identified leading biomarkers that are critical for progressing research and development of several target cancers The key lead biomarker for ColoSTAT®, Rhythm’s initial bowel cancer product, offers a...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

ASX Health stocks endure another topsy-turvy week ending in red Monash IVF makes two key purchases to expand its foothold in fertility sector Actinogen Medical to push ahead with trial into treatment of early Alzheimer’s disease. Healthca...

Rhythm Biosciences (RHY) files ColoSTAT with the Australian TGA for listing on the Australian Register of Therapeutic Goods (ARTG) TGA approval is needed for Rhythm and its partners to market and sell ColoSTAT in the Australian market Rhyt...

The Rhythm Biosciences Ltd (ASX: RHY) share price is on a rollercoaster ride today following the company’s latest release. It surged 11.57% at market open today before falling to $1.18 — 2.5% lower than its previous close. However, the me...

Race Oncology is set to commence Phase 1 study of Zantrene after being given governance approval Rhythm Biosciences has filed blood test ColoSTAT with the TGA Proteomics gets $400k government funding Race Oncology (ASX:RAC) has just recei...

ASX to rise this morning despite sharp falls on Wall Street US CPI is persistently high, but may have reached a peak Bitcoin falls below US$30k Sticky US inflation drags Wall Street lower Aussie shares are set to open marginally higher th...

Transformative cancer diagnostics technology company Rhythm Biosciences (RHY) closes its final ColoSTAT clinical trial site The closure of all the clinical trial sites signifies the finality of clinical trial operations, marking another mi...

Today, Stockhead is having a bit of a moment. We’re just a couple of months shy of being a part of ASX small caps investors’ daily lives for five years. It’s hard to believe that since kicking off with all you need to know about Analytica’s...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Prescient Thereapeutics gives hope with its personalised Car-T cell therapy Imugene working to activate the immune systems of cancer suffers to fight disease Rhythm Bioscience revolutionising the detection of bowel cancer According to th...

Elio D’Amato, Spotee Connect BUY RECOMMENDATIONS Rhythm Biosciences (RHY)   The ColoSTAT screening test achieved a high sensitivity rate in detecting colorectal cancer. It’s estimated the test is 35 per cent more accurate than current globa...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

It’s been an emotional ride for fans of the ASX200 (XJO) which, alongside the Emerging Companies (XEC) index, (down 0.6%) gave up its early gains in a topsy-turvy Monday session. Just after the close, the XJO was weepingly flat – well, up 0...

S&P/ASX 200 healthcare index modestly up 0.16% for week Gut health company Microba falls on IPO Rhythm Biosciences bowel cancer blood screening test milestone Have a habit of forgetting where you put your keys or mobile phone? You ma...

ASX Emerging Companies (XEC) Index is about 1.25% higher ahead of the close on Monday Iron ore shakes $US160, Aussie rattles US75¢ Major movers today: Top End Energy (ASX:TEE), Golden Deeps (ASX:GED), Sayona Mining (ASX:SYA)   The ASX Eme...

Rhythm Biosciences (RHY) “successfully achieves” the end points for its clinical trial (study seven) of its ColoSTAT blood test ColoSTAT is a simple, low-cost blood test for detecting colorectal cancer that has the potential to ultimately...

Rhythm Biosciences releases positive results of ColoSTAT MedAdvisor’s acquisition Adheris exceeds revenue target In a major development today, Rhythm Biosciences (ASX:RHY) was up 15% after announcing that its blood test product ColoSTAT e...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...